These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23174090)

  • 61. Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.
    Kantrowitz JT; Halberstam B; Gangwisch J
    J Clin Psychiatry; 2015 Jun; 76(6):737-8. PubMed ID: 26132675
    [No Abstract]   [Full Text] [Related]  

  • 62. Low-Dose d-Cycloserine for Depression?
    Kim SW; Kushner MG; Yoon G; Anker J; Grant JE
    J Clin Psychiatry; 2016 Aug; 77(8):e1007. PubMed ID: 27561144
    [No Abstract]   [Full Text] [Related]  

  • 63. Augmenting transcranial direct current stimulation with (D)-cycloserine for depression: a pilot study.
    Chan HN; Alonzo A; Martin DM; Mitchell PB; Sachdev P; Loo CK
    J ECT; 2013 Sep; 29(3):196-200. PubMed ID: 23792778
    [TBL] [Abstract][Full Text] [Related]  

  • 64. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 65. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.
    Moskal JR; Burch R; Burgdorf JS; Kroes RA; Stanton PK; Disterhoft JF; Leander JD
    Expert Opin Investig Drugs; 2014 Feb; 23(2):243-54. PubMed ID: 24251380
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study.
    Mohammadi MR; Yadegari N; Hassanzadeh E; Farokhnia M; Yekehtaz H; Mirshafiee O; Akhondzadeh S
    Clin Neuropharmacol; 2013; 36(6):179-84. PubMed ID: 24201232
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
    Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
    Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
    Burgdorf J; Zhang XL; Nicholson KL; Balster RL; Leander JD; Stanton PK; Gross AL; Kroes RA; Moskal JR
    Neuropsychopharmacology; 2013 Apr; 38(5):729-42. PubMed ID: 23303054
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A randomized controlled trial of intranasal ketamine in major depressive disorder.
    Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
    Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
    Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial.
    Husain MI; Chaudhry IB; Husain N; Khoso AB; Rahman RR; Hamirani MM; Hodsoll J; Qurashi I; Deakin JF; Young AH
    J Psychopharmacol; 2017 Sep; 31(9):1166-1175. PubMed ID: 28857658
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of child anxiety disorders via guided parent-delivered cognitive-behavioural therapy: randomised controlled trial.
    Thirlwall K; Cooper PJ; Karalus J; Voysey M; Willetts L; Creswell C
    Br J Psychiatry; 2013 Dec; 203(6):436-44. PubMed ID: 23969483
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effects of sleep extension and sleep hygiene advice on sleep and depressive symptoms in adolescents: a randomized controlled trial.
    Dewald-Kaufmann JF; Oort FJ; Meijer AM
    J Child Psychol Psychiatry; 2014 Mar; 55(3):273-83. PubMed ID: 24252173
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.